TCR, a joint venture involving Imperial Innovations and UCL Business, has been acquired by Cell Medica, itself backed by Touchstone Innovations.
Immunotherapy producer Cell Medica today acquired UK-based cell therapy developer Catapult Therapy TCR for an undisclosed sum.
TCR is a joint venture of Imperial Innovations and UCL Business, the respective tech transfer offices of Imperial College London (ICL) and University College London (UCL), and the Cell and Gene Therapy Catapult, one of several R&D centres established by state-owned innovation agency Innovate UK.
TCR focuses on treatments for acute myeloid leukaemia and myelodysplastic syndrome. The approach also has the potential to…
